NGL Fine-Chem Limited

NSE NGLFINE.NS

NGL Fine-Chem Limited Revenue for the year ending March 31, 2024: USD 40.61 M

NGL Fine-Chem Limited Revenue is USD 40.61 M for the year ending March 31, 2024, a 20.01% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

NGL Fine-Chem Limited Revenue for the year ending March 31, 2023 was USD 33.83 M, a -17.88% change year over year.
NGL Fine-Chem Limited Revenue for the year ending March 31, 2022 was USD 41.20 M, a 18.30% change year over year.
NGL Fine-Chem Limited Revenue for the year ending March 31, 2021 was USD 34.83 M, a 76.19% change year over year.
NGL Fine-Chem Limited Revenue for the year ending March 31, 2020 was USD 19.77 M, a -8.90% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NSE: NGLFINE.NS

NGL Fine-Chem Limited

CEO	Mr. Rahul Jayant Nachane
IPO Date	July 8, 2022
Location	India
Headquarters	301, E Square
Employees	682
Sector	Health Care
Industries Pharmaceuticals

Description

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin for animal health applications; and nitazoxanide, atovaquone, and ranolazine for human health applications. The company also provides various intermediate products; and finished dosage forms in granules and tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.

Key trends

Past 5 years